Results 171 to 180 of about 29,030 (239)

Disproportionality analysis of drug-associated progressive multifocal leukoencephalopathy using spontaneous reports: A 20-year signal detection study based on the FAERS database. [PDF]

PLoS One
Wang H, Li X, Shangguan L.
europepmc   +1 more source

Disease-Modifying Treatment Options in Very Early Onset Multiple Sclerosis-What Choices Are There for Onset Under 5 Years of Age? A Systematic Review. [PDF]

J Clin Med
Craiu D, Dica AD, Pomeran C, Pescaru G, Menascu S, Simu M.   +5 more
europepmc   +1 more source

Balancing innovation and affordability in relapsing-remitting multiple sclerosis: a budget impact analysis from Saudi Arabia. [PDF]

Front Public Health
Al-Jedai A, Almudaiheem H, Al-Suweidan F, Jumah MA, Al-Thobaiti A, Alzureiqan F, Abu Ras W, Al-Dosari FM, Malik YA, Dhopte P, Ojeil R.   +10 more
europepmc   +1 more source

Refining predictors of long-term NEDA-3 status in relapsing-remitting multiple sclerosis: insights from real-world data. [PDF]

Neurol Sci
Guerra T, Bianco A, Esposto C, Intini D, Amati F, Guglielmini G, Caputo F, Paolicelli D, Iaffaldano P.   +8 more
europepmc   +1 more source

Drug-induced peripheral nerve palsy: a real-world study based on FAERS data from 2004 to the third quarter of 2024. [PDF]

Front Pharmacol
Li Y, Yi X, Yu N.
europepmc   +1 more source

External validation of the budget impact analysis of the drug fingolimode in the treatment of multiple sclerosis. [PDF]

Cost Eff Resour Alloc
Campello CRS, da Costa MGS, Pinto M.
europepmc   +1 more source

Inflammatory bowel disease therapies and demyelinating diseases: a practical guide to therapeutic benefit and risk. [PDF]

J Crohns Colitis
Honap S, Debouverie M, Filippi M, Selchen D, Jairath V, Danese S, Peyrin-Biroulet L.   +6 more
europepmc   +1 more source

Natalizumab-Associated Progressive Multifocal Leukoencephalopathy After Natalizumab Extended Interval Dosing Therapy in Japan. [PDF]

Neurol Neuroimmunol Neuroinflamm
Takahashi K, Nakahara J, Miura Y, Ae R, Nakamichi K, Harada M, Mori K, Sanjo N, Yukitake M, Yokote H, Hamaguchi T, Yamada M, Takao M.   +12 more
europepmc   +1 more source

Clinical Experience With Biologic Disease-Modifying Therapy in Relapsing-Remitting Multiple Sclerosis: A Case Report and Review of Literature. [PDF]

Clin Case Rep
Nazneen PS, Dorji T, Yangzom S, Natarajan RV.   +3 more
europepmc   +1 more source

Multiple Sclerosis in Women: Impact of Different Life Stages on Treatment Decisions. [PDF]

CNS Drugs
McConville K, Bove R.
europepmc   +1 more source